Stay updated on AstraZeneca PLC ADR Press Releases

Sign up to get notified when there's something new on the AstraZeneca PLC ADR Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AstraZeneca PLC ADR Press Releases page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    Added a new Baxdrostat Phase III results press release with dates (9M and Q3 2025) and Bax24 details. Removed two older press releases (Saphnelo CHMP recommendation and POTOMAC trial) from the listing.
    Difference
    4%
    Check dated 2025-11-11T03:29:04.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Added four new press release items to the top of the Press Releases page, including Gefurulimab MG-ADL PREVAIL Phase III results and related meeting references with dates in October 2025. Removed several navigation elements, social media links, and older press releases from the page.
    Difference
    7%
    Check dated 2025-11-03T21:41:23.000Z thumbnail image
  4. Check
    34 days ago
    Change Detected
    Summary
    Summary of changes: There are several high-importance additions signaling new approvals and trial results (eg, Enhertu-related outcomes, Tezspire and Saphnelo developments, conditioning on regulatory status) and date stamps; deletions retract or modify prior trial-result claims and corporate actions (eg, Baxdrostat, Enhertu trial outcomes, listing harmonisation, and some approval predictions). Overall, the additions introduce newer positive trial results and regulatory updates, while deletions remove or soften some earlier claims, indicating an overall movement toward updated, more nuanced drug development news rather than a simple expansion of existing content.
    Difference
    91%
    Check dated 2025-10-20T17:12:17.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Major new corporate announcements, manufacturing investment plans, and trial milestones added; removing older trial updates. Overall, the page now emphasizes strategic initiatives and current pivotal trial results rather than earlier September items.
    Difference
    84%
    Check dated 2025-10-13T11:54:47.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Major new trial outcomes and corporate listing harmonization added; older trial/regulatory items removed. Overall, the page content shifts toward newer high-impact biomedical results and corporate actions.
    Difference
    84%
    Check dated 2025-10-06T06:55:54.000Z thumbnail image
  7. Check
    55 days ago
    Change Detected
    Summary
    Update: Adds new regulatory milestones (Enhertu+pertuzumab US Priority Review; Koselugo EU CHMP recommendation; Tezspire EU CHMP recommendation) with dates) and removes several older items (EU CHMP opinion for Trixeo, PREVAIL trial result, AstraZeneca investment plan).
    Difference
    80%
    Check dated 2025-09-29T03:29:53.000Z thumbnail image

Stay in the know with updates to AstraZeneca PLC ADR Press Releases

Enter your email address, and we'll notify you when there's something new on the AstraZeneca PLC ADR Press Releases page.